- Vast opportunities exist in growing cannabis space
- CannAssist is committed to establishing aggressive marketing presence in promising market
- CannAssist brings impressive advancements, achievements to the table, including its propriety CiBiDinol technology
Carefully developing and executing a strategic go-to-market plan has never been more important for companies operating in the cannabis industry, according to a recent “Rolling Stone” article (https://cnw.fm/uMoi5). The article urges cannabis companies to consider the industry from both a competitive perspective as well as an opportunity angle, which is exactly what CannAssist International (OTCQB: CNSC) has done as it looks toward 2021 and a projected $5.8 million share of the market.
“The 2020 election was another exciting turning point: Four new states joined the 12 existing markets with legal recreational cannabis, bringing adult use to 15 regions in just eight short years,” the “Rolling Stone” article reported. “Nearly one in three Americans now live in a state where those aged 21 and older can purchase and possess cannabis freely. This will likely expand significantly with the addition of more East Coast markets poised to legalize in the near future through legislation in New York, Pennsylvania and Connecticut.
“It gets even better,” the article continued. “With a new federal administration comes the likelihood of a mandate to decriminalize cannabis and a path to legalization through bills in Congress such as the passing of the MORE Act by the House of Representatives, with its lead sponsor Vice President Kamala Harris. Consumer sentiment favoring legalization is expanding. According to findings from Pew Research from 2019, two-thirds of Americans approve of adult-use in what has become one of those rare bipartisan issues with differences of opinion occurring predominantly along generational lines.”
CannAssist recognizes the wave of opportunity flooding the cannabis market and is committed to establishing an aggressive marketing presence using tactics across the entire marketing funnel plan as part of its go-to-market strategy (https://cnw.fm/cDw0H). In part, the company will focus on retail partnership, brand collaborations and influencer programming. In addition, CannAssist is eyeing large-scale video and content capture and will also evaluate avenues for digital advertising, email marketing, and both paid and organic social media engagement.
These efforts are designed to support the company’s efforts to reach its goals in five key product areas: Xceptol Capsules M($1 million), Xceptol Drops ($532,000), Xceptol Pain Cream ($1.27 million), Xceptol Pet product ($130,000), and raw material from its Xceptor Labs ($1.48 million). CannAssist owns Xceptor Labs, which produces and markets the Xceptol brand product line and also produces superior quality raw materials for third-party company use.
A biotechnological pharmaceutical and wellness company, CannAssist brings impressive advancements and achievements to the table—none more notable than its development of CiBiDinol, which simply put is cannabidiol made water compatible (https://cnw.fm/JGyB1). CiBiDinol addresses critical issues regarding CBD molecules, including delivery, bioavailability and short shelf life, by offering predictable potency, reduced dosage requirements and a wider variety of product forms.
Established in May 2017, CannAssist is headquartered in San Diego County, California, and markets its consumer line of cannabidiol (“CBD”) products under the Xceptol brand. CNSC is currently targeting North America, Central America, South America, South Africa, the EU, the UK and the Philippines as viable product markets. The company has established strategic partnerships in sourcing, manufacturing, processing, laboratory, distribution, public relations and legal representation.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://cnw.fm/CNSC
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
